tbuckley/cabot-search huggingface dataset:
PTU-039 Colonoscopic Polyp Detection Rate is Stable Throughout the Workday including in evening Colonoscopy Sessions
Authors: D Thurtle, M Pullinger, J Tsigarides, I Mcintosh, C Steytler, I L P Beales
Journal: Gut (2013)

Since Ontario introduced auto-insurance legislation that guaranteed extensive physiotherapy treatment for people who have been in car accidents, the cost of outpatient claims to insurance companies has skyrocketed. However, there has not been a measurable improvement in patient outcomes. At the same time, the average in-hospital stay for patients receiving hip and joint replacements has decreased greatly. Dr. Murray Waldman thinks these divergent trends in rehabilitation can be attributed to physician self-interest.
Abstract P1-01-06: Evaluation of the stage IB designation of the 7th edition of the AJCC staging system: Biologic factors are more important
Authors: EA Mittendorf, KV Ballman, LM McCall, N Hansen, A Lucci, S Gabram, M Urist, J Crow, T Hurd, KK Hunt, AE Giuliano
Journal: Cancer Research (2012)

Abstract Purpose: The stage IB designation was added to the AJCC 7th edition staging system to denote micrometastasis in patients with T1 tumors. We have previously examined this group and found that receptor status and nuclear grade were better survival discriminates than the presence of micrometastases. The current study was undertaken to validate this finding in a larger cohort from the American College of Surgeons Oncology Group (ACOSOG) Z0010 study. Methods: Clinicopathologic and outcomes data from patients enrolled on ACOSOG Z0010 were recorded. All patients underwent breast conserving surgery, sentinel lymph node biopsy and whole breast radiation for clinical T1-2, N0 breast cancer. Sentinel lymph nodes were evaluated by H&amp;E locally and if negative, by immunohistochemistry (IHC) at a central laboratory. Patients were staged according to the 7th edition AJCC system and recurrence-free (RFS), disease-specific (DSS) and overall survival (OS) were determined using the Kaplan-Meier method and compared using the log-rank test. Results: There were 5210 eligible and evaluable patients enrolled on ACOSOG Z0010. AJCC stage distribution was known in 4590 and included: 2849 (62.0%) stage IA, 376 (8.2%) stage IB, 878 (19.1%) stage IIA, 322 (7.0%) stage IIB, and 170 (3.7%) stage III. Median follow-up for the cohort was 9.0 years (range 0–12.6). Five and 10-year RFS, DSS and OS rates for patients with stage IA versus IB disease are shown in table 1. There were no significant differences between groups. When all stage I patients (stage IA and IB) were evaluated by ER status (positive vs negative) or grade (grade 1 vs 2 vs 3), these biologic factors were able to significantly discriminate patients with respect to RFS, DSS and OS (table 2). Conclusion: Differentiating patients with micrometastases (stage IB) from node negative patients (stage IA) does not stratify patients well with respect to survival. Biologic factors including ER status and grade are better discriminants of survival than the presence of small volume nodal metastases in patients with early stage breast cancer. Breast cancer staging should include biologic factors from the primary tumor. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-01-06.
Reply to Xin et al.
Authors: O. Möschler
Journal: Endoscopy (2011)

We thank Xin et al. for their comments. We agree that the definitions of complete enteroscopy are heterogeneous. The definition of the complete enteroscopy rate in double-balloon endoscopy (DBE) examinations as the ratio of cases with DBE successfully passing through the entire small bowel over the total number of cases in which attempts to examine the entire small bowel are made was used in our database to describe the complete enteroscopy rate of 21 %. The 23 % used in the discussion section is an error, for which we apologize.
Abstract 5381: p62/IMP2 promotes hepatocellular carcinoma (HCC) progression.
Authors: Ningjing Lei, Bo Peng, Yang Li, Yurong Chai, Jianying Zhang
Journal: Cancer Research (2013)

Abstract Autoantibodies to autologous cellular antigens in cancer patients have been considered as reporters identifying antigenic changes in cellular factors involved in the transformation process. We have made use of such autoantibodies from hepatocellular carcinoma patients to immunoscreen a cDNA expression library and have identified a cytoplasmic RNA-binding protein p62. Autoantibodies to p62 have been detected in up to 21% of a cohort of hepatocellular carcinoma (HCC) patients. Further study has demonstrated that p62 is a member of insulin-like growth factor 2 mRNA binding protein family (IMPs), which is an isoform of IMP2. The three members of the IMP family (IMP1, 2 and 3) have been found to regulate translation of insulin-like growth factor 2 (IGF2) mRNA in a post-transcriptional manner. Since several studies have suggested that IMP1 and IMP3 play important roles in cancer progression, whether p62/IMP2 can also play a role in cancer formation remains to be investigated. In this study, we intend to interrogate the role of p62/IMP2 in HCC formation. We found that the expression of p62/IMP2 (57.5%) is significantly higher in HCC specimen than that in normal liver tissue (15.4%) by immunohistochemistry study. Furthermore, p62/IMP2 is detected to be overexpressed in several liver cancer cell lines. Depletion of p62/IMP2 via lentivirus-mediated knockdown in SNU449 liver cancer cell line decreased the cell proliferation. On the contrary, the ectopic overexpression of p62/IMP2 increased cell proliferation. Our data suggested that p62/IMP2 is overexpressed in liver cancer and is functionally correlated with cancer cell growth. Citation Format: Ningjing Lei, Bo Peng, Yang Li, Yurong Chai, Jianying Zhang. p62/IMP2 promotes hepatocellular carcinoma (HCC) progression. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5381. doi:10.1158/1538-7445.AM2013-5381
Abstract LB-104: Differences in repair of DNA cross-links between lymphocytes and tumor cells from colon cancer patients
Authors: Mercedes Herrera, Gemma Dominguez, Jose M. Garcia, Cristina Peña, Carmen Jimenez, Javier Silva, Vanesa Garcia, Irene Gomez, Raquel Diaz, Paloma Martin, Felix Bonilla
Journal: Cancer Research (2010)

Abstract The more common approach to comet assay studies with cancer patients involves indirect measurement of the effect of antineoplastic drug or radiation regimen by assessing DNA damage in surrogate cells, such as peripheral blood lymphocytes of cancer patients, to predict how tumor cells may be affected. The aim of the present study was to compare the capability of different cells isolated from a series of 23 colon cancer patients to repair the damage induced by a cancer drug. We adapted the in vitro comet repair assay for nucleotide excision repair to measure the ability of lymphocytes and normal and tumor epithelial colon cells to remove DNA cross-links induced by oxaliplatin. The excision repair rate was measured quantitatively by the tail parameters: tail DNA, tail length, extent tail moment, and olive tail moment. Kruskal-Wallis analysis revealed significant differences in recognition and excision activity between different cell types (P &amp;lt; 0.001) for all the comet parameters studied. Hence, colon cells showed higher recognition and excision activity than lymphocytes and tumor cells displayed the highest repair capability. We found no significant correlation between the repair activity of tumor colon cells and lymphocytes in any of the comet parameters considered. Our data support the view that lymphocyte repair activity is not predictive of the repair ability of the tumor and that lymphocytes cannot act as surrogate cells. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-104.
Abstract 4450: Cisplatin intercalated zirconium phosphate nanoparticles are cytotoxic to MCF-7 breast cancer cells via apoptosis
Authors: Millie L. Gonzalez, Mayra Ortiz, Adriana Baez
Journal: Cancer Research (2011)

Abstract Purpose: Nanoparticle-mediated drug delivery has great potential for anticancer therapy. The purpose of this study was to determine the effectiveness of zirconium phosphate (ZrP) nanoparticles as carrier of the cytotoxic drug cisplatin in MCF-7 breast cancer cells. Methods: Cytotoxicity of ZrP, ZrP:cisplatin, and cisplatin were studied using the MTT Assay. Cell cycle analyses and apoptosis were analyzed using flow cytometry technology. Results: ZrP nanoparticles were not cytotoxic to MCF-7 cells. However, cell viability was reduced to 70% when MCF-7 cells were grown with ZrP: cisplatin 100μM. Cisplatin was cytotoxic to MCF-7 cells with an IC50 of 10 μM. The cytotoxic effect of cisplatin: ZrP is mediated by induction of apoptosis. AnnexinV/PI treated MCF-7 cells showed the apoptotic events in cisplatin -induced apoptosis. ZrP nanoparticles alone did not cause apoptosis to MCF-7 cells or peripheral blood lymphocytes. Conclusion: ZrP nanoparticles can significantly reduce side effects associated to systemic toxicity of anticancer agents and more studies are warranted. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4450. doi:10.1158/1538-7445.AM2011-4450
Abstract 2182: IGFBP-6 in nasopharyngeal carcinoma is a candidate tumor suppressor gene by regulating the expression of EGR-1
Authors: Yuan-Sung Kuo, Chin-Tarng Lin, Han-Chung Wu
Journal: Cancer Research (2011)

Abstract Nasopharyngeal carcinoma (NPC) is one of the common cancers in South-Eastern Asia, particularly southern China, Singapore and Taiwan. It has been proposed to be closely associated with Epstein-Barr virus (EBV), but other researches also show that EBV can enhance the NPC proliferation but not related with initiation or promotion of NPC carcinogenesis. The aim of this study was to identify the pivotal genes that may be altered during NPC progression. Using cDNA microarray analysis, we compared the expression of 18 genes between NPC and normal nasomucosal cells. Q-RT-PCR analysis found the expression of IBFBP-6 in NPC cell lines and immunolocalization of IGFBP-6 in NPC cells and biopsy specimens to be very weak. To explore the effects of IGFBP-6 on NPC tumor growth, we constructed inducible plasmids containing full-length IGFBP-6 cDNA (pBIG2i-IGFBP-6) and established pBIG2i-IGFBP-6-transfected NPC stable cell lines (NPC-TW01-pBIG2i-IGFBP-6). We then performed in vitro and in vivo functional analysis of the IGFBP-6 in these cell lines. Over-expression of IGFBP-6 significantly suppressed the proliferation, invasion and metastatic activity of NPC cells and increased their apoptosis. We found the EGR-1, caspase-1 and TSP-1 genes to be markedly up-regulated when NPC-TW01-pBIG2i-IGFBP-6 was treated with doxycycline. Knocking down EGR-1 with EGR-1 siRNA resulted in a decrease in expression of caspase-1, TSP-1 and EGR-1 but not the expression of IGFBP-6. However, in knockdown cells the unchanged expression of IGFBP-6 did not inhibit the migration of NPC cells. Chromatin immunoprecipitation and luciferase reporter assay experiments showed that IGFBP-6 bound the EGR-1 promoter regions and activated EGR-1 promoter. We conclude that IGFBP-6 can regulate the progression of NPC by regulating the expression of EGR-1. These results suggest that IGFBP-6 could be used as a new target for NPC therapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2182. doi:10.1158/1538-7445.AM2011-2182
Abstract 3880: Synthesis of complex oligonucleotide libraries enables flexible and precise high-resolution fluorescence imaging of cellular nucleic acids
Authors: Robert A. Ach, N. Alice Yamada, Peter Tsang, Alicia Scheffer-Wong, Laurakay Bruhn
Journal: Cancer Research (2011)

Abstract Fluorescence in situ Hybridization (FISH) is a powerful technique for studying chromosome structure, organization, and stability. To date, the use of FISH has been largely dependent upon access to cloned template DNA for the generation of probes. Clones for specific regions may be unavailable, or the genomic region of interest may contain repetitive and other non-informative sequences which can be problematic for FISH analysis. We have leveraged our ability to chemically synthesize DNA in massively parallel reactions to produce libraries of oligonucleotides up to 200 bases in length that can be used to generate FISH probes. The sequences of the oligonucleotides in these libraries are selected in silico using empirically determined criteria so as to avoid repetitive elements or regions homologous to other non-targeted loci, thus targeting only the most informative elements in the region of the genome to be analyzed. We demonstrate that using our FISH technique, human genomic regions as small as 1.8 kb and as large as whole chromosomes can be visualized in both metaphase and interphase cells using the same simple assay protocol. In addition, specific and robust signals can readily be obtained for chromosomal regions rich in repeats and/or GC content. These libraries can also be used to determine the localization of cellular RNAs. Co-detection of both nuclear proteins by immunocytochemistry and fluorescent imaging of chromosome domains has also been demonstrated. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3880. doi:10.1158/1538-7445.AM2011-3880
SAT0020 Cross Cultural Adaptation and Validation of Lupuspro in Southern Chinese Patients with Systemic Lupus Erythematosus: Table 1.
Authors: C.C. Mok, M. Kosinski, M. Jolly
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> LupusPRO is a disease targeted patient reported health outcome measure that was developed and validated for use among US patients with Systemic Lupus Erythematosus (SLE). It has been cross culturally adapted and validated in other languages. <h3>Objectives</h3> To present results of cross-cultural adaptation of LupusPRO into Chinese language, and test its psychometric properties among southern Chinese patients with SLE in Hong Kong <h3>Methods</h3> LupusPRO was translated into "Traditional" Chinese using forwards and backwards translation methods, followed by pretesting among five native Chinese speakers. Based on the feedback obtained, the translated tool was revised until no issues on feedback from pretesting were noted. The Chinese language LupusPRO tool was administered along with generic Quality of life tool (MOS-SF36) to SLE patients meeting 4 ACR classification criteria. At the same time, demographic, clinical data (ACR criteria, medications), disease activity (SELENA-SLEDAI) and damage (SLICC-ACR/SDI) were obtained. We tested the reliability (Internal consistency reliability-ICR), validity (convergent (CV) and criterion validity), factor analysis of the Chinese LupusPRO. Weak correlation between LupusPRO and disease activity was expected due to a priori and unique PRO information captured by the tool. <h3>Results</h3> 463 SLE patients (95% Females) with a mean (SD) age of 42.3 (13.5) yrs participated. Ninety five percent were women. Mean (SD) disease duration was 9.9 (7.5) years. The mean (SD) PGA, SELENA-SLEDAI and SDI were 0.48 (0.45), 2.9 (3.0) and 0.7 (1.2) respectively. Sixty percent were on steroids and 64% on hydroxy-chloroquine. The ICR of the LupusPRO domains ranged from 0.60-0.94. LupusPRO domains had CV against corresponding SF36 domains (Table 1). Significant but weak correlation with disease activity was noted for criterion validity. Factor Analysis conformed to the model, except for the two Lupus Medication items and one item on "worry about income" showing cross loadings onto other domains. <h3>Conclusions</h3> Chinese language LupusPRO has fair psychometric properties, and may be used in SLE clinical trials. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3182
AB0582 Effect of Vitamin D Deficiency and Replacement on Endothelial Functions in Familial Mediterrenean Fever
Authors: M. Can, R. Eren, O. Baykan, O. Asmaz-Haliloglu, D. Gogas-Yavuz, G. Haklar, H. Direskeneli
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Although patients with familial Mediterranean fever (FMF) are symptom-free between the attacks, subclinical inflammation may continue. Vitamin D (vit D) plays an important role in the modulation of immune system and might also influence the course of FMF. Endothelial dysfunction is previously demonstrated in Behcet9s disease (BD) and vit D is implicated to modulate endothelial functions. <h3>Objectives</h3> We aimed to evaluate the status of serum 25(OH)Vit D3 levels and its association with disease activity, endothelial function and carotis intima media thickness (CIMT) in patients with FMF. <h3>Methods</h3> Sixty-two FMF (F/M: 42/20, mean age: 33.5 years), 43 ankylosing spondylitis (AS) (F/M: 19/24, mean age: 40.9 years) patients and 46 healthy controls (HC) (F/M: 26/20, mean age: 34.7 years) were studied. Serum 25(OH)Vit D3 levels were measured by HPLC method. Endothelial function was evaluated by brachial artery flow mediated dilatation (FMD) and CIMT with B-Mode ultrasound. The vitamin D-deficient BD patients received 1000 IU Vitamin D3 daily for 3 months. At the end of the third month of treatment, the subjects were re-evaluated for the same parameters (CIMT and FMD). <h3>Results</h3> The mean (SD) disease duration was 8.2 (7.8) vs 8.4 (6.5) years (p&gt;0.05) in FMF and AS patients, respectively. All FMF patients were on attack-free period and all of them were on colchicine treatment. A significant difference was observed between the levels of 25(OH)Vit D3 between the groups [median (range): 11.3 (2.7-48.3), 12.7 (4-37) and 56 (14-125), FMF, AS and HC, respectively), p=0,001]. CIMT and FMD measurements were similar between groups (p&gt;0.05). Serum 25(OH)Vit D3 levels were not observed to correlate with CIMT or FMD measurements. A significant increase of 25(OH)VitD3 levels after replacement therapy [11.3 (2.7-48.3), vs 30 (13-72) p=0.001] was observed after 3 months of therapy. Also, after replacement therapy, CIMT measurements improved (1,04 vs 0.50, p=0.001) and FMD measurements improved (4,9 vs 10,2, p=0.01) <h3>Conclusions</h3> A high presence of Vitamin D deficiency was observed in FMF patients from Turkey. Although impaired vascular endothelial function did not correlate with vitamin D levels, vitamin D deficiency may influence the course of the attacks and be related to some colchicine-resistant cases. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5994
Acute “balloon pancreatitis”
Authors: Constance Geffrier, Elia Samaha, Henri Duboc
Journal: Endoscopy (2014)

Intragastric balloon (IGB) placement is an endoscopic treatment for obesity, which offers a less invasive alternative to bariatric surgery. Severe complications, which occur in less than 1 % of cases, relate mostly to gastric perforation and intestinal obstruction. Two cases of pancreatitis have been reported to date [1] [2].
SAT0476 Impact of etanercept-methotrexate therapy on patient-reported outcomes in a randomized controlled trial in moderately active rheumatoid arthritis patients:
Authors: P. Bird, J. Wollenhaup, S.-H. Lee, Z. Szekanecz, O. Neira, C. Hammond, B. Vlahos, A. Szumski, A.S. Koenig, S. Kotak
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Normalization of physical function and health-related quality of life (HR-QoL) is an important treatment goal in patients with rheumatoid arthritis (RA), including those with moderately active disease despite MTX use. Increasing treatment costs, particularly for very effective but expensive biologic agents, have also triggered interest in exploring optimal treatment strategies such as "induction-then-maintenance" regimens. <h3>Objectives</h3> To compare patient-reported outcomes (PROs) achieved with continuing etanercept (ETN) 50 mg QW + methotrexate (MTX; E50/M), reducing ETN from 50 mg to 25 mg QW + MTX (E25/M), and replacing ETN with placebo + MTX (P/M) over 52 wks after induction of sustained response during 36 wks of E50/M. <h3>Methods</h3> Patients with moderately active RA (DAS28 of &gt;3.2 and ≤5.1) who achieved DAS28 low disease activity (LDA; DAS28 ≤3.2, avg wk 12–36 + at wk 36) during the 36-wk open-label induction phase with E50/M were randomized to double-blind treatment with E50/M (n=202), E25/M (n=202), or P/M (n=200) for 52 wks. PROs included: HAQ; EQ-5D; Medical Outcomes Study Sleep Scale (MOS-SS) Problem I Index; Brief Pain Inventory (BPI); Functional Assessment of Chronic Illness Therapy (FACIT); and Work Productivity Activity Impairment Questionnaire: RA (WPAI:RA). <h3>Results</h3> The adjusted mean changes in HAQ, EQ-5D, and WPAI:RA % activity impairment due to RA from wks 36–88 were statistically significantly smaller with E50/M and E25/M vs P/M (table; p&lt;0.0001), indicating less deterioration. Significant differences favoring E50/M and E25/M vs P/M were also observed in the MOS-SS, BPI, FACIT, and WPAI:RA % impairment due to RA while working (p&lt;0.05). The adjusted mean change in % overall work impairment due to RA was significantly smaller with E50/M than with E25/M and P/M at wk 88 (p&lt;0.01). A significantly higher % of patients in the E50/M and E25/M groups reached HAQ Δ ≥0.22 and EQ-5D index Δ ≥0.05 from wks 0 to 88 (p&lt;0.01). <h3>Conclusions</h3> In patients with moderate RA disease activity, after induction and maintenance of LDA, etanercept full- and reduced-dose combination regimens were superior to step-down treatment with MTX alone in their effects on PROs. Overall, minimal differences in PROs were observed between the full- and reduced-dose combination treatment groups. <h3>Disclosure of Interest</h3> P. Bird: None Declared, J. Wollenhaup Consultant for: Pfizer Inc, S.-H. Lee: None Declared, Z. Szekanecz: None Declared, O. Neira Consultant for: Pfizer Inc, C. Hammond Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, B. Vlahos Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, A. Szumski Employee of: Pfizer Inc, A. S. Koenig Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, S. Kotak Shareholder of: Pfizer Inc, Employee of: Pfizer Inc